X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cancer (2) 2
cancer therapies (2) 2
chemotherapy (2) 2
inhibition (2) 2
oncology (2) 2
ovarian cancer (2) 2
patients (2) 2
administration, intravenous (1) 1
administration, oral (1) 1
adult (1) 1
aged (1) 1
amg 386 (1) 1
analysis (1) 1
angiogenesis (1) 1
angiopoietin (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
bevacizumab (1) 1
biopsy (1) 1
brca1 protein - genetics (1) 1
brca2 protein - genetics (1) 1
carboplatin (1) 1
carboplatin - administration & dosage (1) 1
carcinoma (1) 1
care and treatment (1) 1
cisplatin (1) 1
clinical medicine (1) 1
clinical trials (1) 1
colitis (1) 1
combination (1) 1
deoxyribonucleic acid--dna (1) 1
disease-free survival (1) 1
diseases (1) 1
drug administration schedule (1) 1
dyspnea (1) 1
edema (1) 1
enzyme inhibitors - administration & dosage (1) 1
enzyme inhibitors - adverse effects (1) 1
fallopian tube (1) 1
female (1) 1
functional assessment (1) 1
gene mutations (1) 1
gynecology (1) 1
hematology, oncology and palliative medicine (1) 1
hospitals (1) 1
humans (1) 1
index medicus (1) 1
intravenous administration (1) 1
liposomal doxorubicin (1) 1
maintenance therapy (1) 1
middle aged (1) 1
molecular targeted therapy (1) 1
monosaccharides (1) 1
motivation (1) 1
multicenter (1) 1
mutation (1) 1
neoplasm grading (1) 1
neoplasm recurrence, local (1) 1
neoplasms, cystic, mucinous, and serous - drug therapy (1) 1
neoplasms, cystic, mucinous, and serous - enzymology (1) 1
neoplasms, cystic, mucinous, and serous - mortality (1) 1
neoplasms, cystic, mucinous, and serous - pathology (1) 1
neutropenia (1) 1
obstetrics (1) 1
open-label (1) 1
ovarian neoplasms - drug therapy (1) 1
ovarian neoplasms - enzymology (1) 1
ovarian neoplasms - genetics (1) 1
ovarian neoplasms - mortality (1) 1
ovarian neoplasms - pathology (1) 1
paclitaxel (1) 1
paclitaxel - administration & dosage (1) 1
pain (1) 1
peritoneum (1) 1
phthalazines - administration & dosage (1) 1
phthalazines - adverse effects (1) 1
piperazines - administration & dosage (1) 1
piperazines - adverse effects (1) 1
poly polymerase inhibitors (1) 1
poly polymerases - metabolism (1) 1
polymerase (1) 1
product development (1) 1
protein-tyrosine kinase (1) 1
protein-tyrosine kinase receptors (1) 1
relapse (1) 1
solid tumors (1) 1
studies (1) 1
sugars (1) 1
suppression (1) 1
surgery (1) 1
survival (1) 1
therapy (1) 1
time factors (1) 1
treatment outcome (1) 1
tumor-growth (1) 1
tumors (1) 1
tyrosine (1) 1
vascular endothelial growth factor (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer
Journal Article
by Vergote, Ignace and Scambia, Giovanni and O'Malley, David and O'Malley, David M and Van Calster, Ben and Park, Sang-Yoon and Park, Sang Yoon and del Campo, Josep M and Meier, Werner and Bamias, Aristotelis and Colombo, Nicoletta and Wenham, Robert M and Wenham, Robert and Covens, Allan and Covens, Al and Marth, Christian and Raza Mirza, Mansoor and Kroep, Judith and Kroep, Judith R and Ma, Haijun and Pickett, Cheryl A and Monk, Bradley J and Monk, Bradley and Song, Yong Sang and Makarova, Yulia and Trinidad, Joshua and Ngan, Hextan Yuen Sheung and Aravantinos, Gerasimos and Nam, Joo-Hyun and Gorbunova, Vera and Krikunova, Ludmila and Bae, Duk-Soo and Arija, Jose Angel Arranz and Mirza, Mansoor Raza and Zamagni, Claudio and Papandreou, Christos and Raspagliesi, Francesco and Lisyanskaya, Alla and Benzaquen, Ana Oaknin and Tognon, Germana and Ortega, Eugenia and Herraez, Antonio Casado and Buscema, Joseph and Green, Andrew and Burger, Robert and Sakaeva, Dina and Sanchez, Andres Redondo and Ghamande, Sharad and King, Laurel and Petru, Edgar and Peen, Ulla and Takeuchi, Satoshi and Ushijima, Kimio and Martin, Antonio Gonzalez and Kamelle, Scott and Carney, Michael and Forget, Frédéric and Bentley, James and Sehouli, Jalid and Zola, Paolo and Kato, Hidenori and Fadeeva, Natalya and Gotovkin, Evgeny and Vladimirov, Vladimir and Marin, Margarita Romeo and Alia, Eva Guerra and Shahin, Mark and Bhoola, Snehalkumar and Tewari, Krishnansu and Anderson, Daniel and Anderson, Jeanne and Honhon, Brigitte and Pelgrims, Joseph (Gino) and Oza, Amit and Jimenez, Jesus Garcia-Donas and Hansen, Vincent and Benjamin, Ivor and Renard, Vincent and Van den Bulck, Heidi and Haenle, Claudia and Koumakis, Georgios and Yokota, Harushige and Popov, Vadim and Bradley, William and Reid, Robert and Reid, Gary and McNamara, Donna and Friedman, Richard and Barlin, Joyce and Spirtos, Nicola and Chapman, Julia and Sevelda, Paul and Huizing, Manon and Lamot, Caroline and Goffin, Frédéric and Hondt, Lionel D and Spadafora, Silvana and Rautenberg, Beate and Reimer, Toralf and Möbus, Volker and ... and TRINOVA-3 ENGOT-ov2 GOG-3001 Inves and TRINOVA-3/ENGOT-ov2/GOG-3001 investigators
The Lancet Oncology, ISSN 1470-2045, 06/2019, Volume 20, Issue 6, pp. 862 - 876
Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has... 
WOMEN | THERAPY | INHIBITION | ANGIOGENESIS | ONCOLOGY | FUNCTIONAL ASSESSMENT | BEVACIZUMAB | SUPPRESSION | TUMOR-GROWTH | AMG 386 | CHEMOTHERAPY | Care and treatment | Analysis | Carboplatin | Clinical trials | Product development | Ovarian cancer | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.